Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-123 for preventing OIPN in mCRC
NCT04492436Phase 2Withdrawn
- Sponsor
- Veloxis Pharmaceuticals
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of thrombomodulin alfa, sponsored by Veloxis Pharmaceuticals. Planned start Oct 2021; status: withdrawn.
02
Drugs
thrombomodulin alfa
Beyond the preview
Go deeper on NCT04492436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492436.